The initial dose of Semavik® is 0.25 mg once a week. After 4 weeks of use, the dose should be increased to 0.5 mg once a week. To further improve glycemic control, after at least 4 weeks of use of the drug at a dose of 0.5 mg once a week, the dose can be increased to 1 mg once a week.
The dose of Semavik® 0.25 mg is not therapeutic. Administration of more than 1 mg per week is not recommended.
The drug Semavik® can be used as monotherapy or in combination with one or more hypoglycemic drugs (see section “Clinical efficacy and safety”).
When adding Semavik® to previous therapy with metformin and/or thiazolidinedione, or an SGLT2 inhibitor, therapy with metformin and/or thiazolidinedione, or an SGLT2 inhibitor can be continued at the same doses.
When adding Semavik® to ongoing therapy with a sulfonylurea derivative or insulin, a reduction in the dose of the sulfonylurea derivative or insulin should be considered in order to reduce the risk of hypoglycemia (see section "Special Instructions").
The use of Semavik® does not require self-monitoring of blood glucose concentrations.
Self-monitoring of blood glucose concentrations is necessary to adjust the dose of sulfonylurea and insulin, especially at the beginning of treatment with Semavik® and when reducing the dose of insulin. It is recommended to use a stepwise approach to reducing your insulin dose.

Compound
1 ml of solution contains:
active ingredient: semaglutide - 1.34 mg;
excipients: disodium hydrogen phosphate dihydrate - 1.42 mg, propylene glycol - 14.0 mg, phenol - 5.5 mg, diluted hydrochloric acid 10% and/or sodium hydroxide solution 10% - to correct pH to 7.4, water for injections - up to 1 ml.

Packaging and release form
Solution for subcutaneous administration, 0.25/0.5/1 mg/dose of 3 ml of the drug in colorless glass cartridges. The cartridge is installed in a plastic multidose disposable syringe pen for multiple injections. 1 pre-filled multi-dose disposable syringe pen for multiple injections and 1 cardboard pack containing 4 disposable needles installed in a cardboard holder for needles, with instructions for medical use of the medicinal product, instructions for using the syringe pen and an insert card for administration control The drug is placed in a cardboard pack.

Special storage conditions
Storage conditions
Store at a temperature between 2 °C and 8 °C (in the refrigerator), but not near the freezer. Protect from light. Do not freeze.
Used or carried as a spare syringe pen with the drug should be stored at a temperature not exceeding 30 ° C or at a temperature from 2 ° C to 8 ° C (in the refrigerator) for 6 weeks.
Do not freeze.
After use, cover the pen with a cap to protect it from light.
Semavik® should be protected from exposure to excess heat and light.
Keep out of the reach of children.